Drug Profile

AB 102 - Arcus Biosciences

Alternative Names: AB-102 - Arcus Biosciences; MRGPRX2 inhibitor - Arcus Biosciences

Latest Information Update: 24 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arcus Biosciences
Class Skin disorder therapies; Small molecules
Mechanism of Action MRGPRX2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Skin disorders
Preclinical Atopic dermatitis; Chronic urticaria

Most Recent Events

05 Aug 2026 Arcus Biosciences plans a clinical trial (In volunteers) (PO) in August 2026.
09 Jul 2026 Phase-I clinical trials in Skin disorders (In volunteers) in Netherlands (PO) (CTIS2026-526279-52-00) (NCT07662057)
05 May 2026 Pharmacodynamics data from a preclinical studies in Atopic dermatitis released by Arcus Biosciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com